U01CA247573
Cooperative Agreement
Overview
Grant Description
Engineering immunotherapeutic probiotics to mitigate IRAE.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 401% from $586,329 to $2,937,508.
The Trustees Of Columbia University In The City Of New York was awarded
Engineering immunotherapeutic probiotics to mitigate irAE
Cooperative Agreement U01CA247573
worth $2,937,508
from National Cancer Institute in January 2020 with work to be completed primarily in New York United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.353 21st Century Cures Act - Beau Biden Cancer Moonshot.
The Cooperative Agreement was awarded through grant opportunity Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 4/19/24
Period of Performance
1/21/20
Start Date
12/31/24
End Date
Funding Split
$2.9M
Federal Obligation
$0.0
Non-Federal Obligation
$2.9M
Total Obligated
Activity Timeline
Transaction History
Modifications to U01CA247573
Additional Detail
Award ID FAIN
U01CA247573
SAI Number
U01CA247573-3811782738
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
F4N1QNPB95M4
Awardee CAGE
1B053
Performance District
NY-90
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,770,158 | 100% |
Modified: 4/19/24